X0303 4 2010-06-17 0001003124 PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPDI 0001412292 Darazsdi Daniel G 929 NORTH FRONT STREET WILMINGTON NC 28401 0 1 0 0 Chief Financial Officer Common Stock 11482 D Stock Options (to buy) 26.64 2010-06-17 4 A 0 30000 0 A 2011-06-17 2020-06-17 Common Stock 30000 30000 D Stock Options (to buy) 20.45 2011-02-25 2020-02-25 Common Stock 62104 62104 D Stock Options (to buy) 25.74 2010-02-18 2019-02-18 Common Stock 62104 62104 D Stock Options (to buy) 19.94 2009-11-20 2018-11-20 Common Stock 23289 23289 D Stock Options (to buy) 37.69 2009-10-03 2018-10-03 Common Stock 23289 23289 D Stock Options (to buy) 43.26 2009-02-20 2018-02-20 Common Stock 46578 46578 D Stock Options (to buy) 34.15 2008-10-01 2017-10-01 Common Stock 93156 93156 D 10,000 shares of restricted stock were granted upon the Reporting Person's acceptance of employment. These shares vest in three equal increments on 10/1/08, 10/1/09 and 10/1/10. These options vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13. Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc. These options vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13. These options vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12. These optons vest in three equal increments on 11/20/09, 11/20/10 and 11/20/11. These options vest in three equal increments on 10/3/09, 10/03/10 and 10/3/11. These options vest in three equal increments on 2/20/09, 2/20/10 and 2/20/11. These options vest in three equal increments on 10/1/08, 10/1/09 and10/1/10. Lisa C. Noecker attorney-in-fact for Daniel G. Darazsdi 2010-06-18